COST-EFFECTIVENESS OF SEQUENTIAL TREATMENT WITH ABALOPARATIDE FOLLOWED BY ALENDRONATE VS ALENDRONATE MONOTHERAPY FOR THE PREVENTION OF FRACTURES IN POSTMENOPAUSAL US WOMEN AT INCREASED RISK OF FRACTURE

被引：0
|
作者：
Hiligsmann, M. [1 ]
Williams, S. [2 ]
Fitzpatrick, L. [2 ]
Silverman, S. [3 ]
Weiss, R. J. [2 ]
Reginster, J. Y. [4 ]
机构：
[1] Maastricht Univ, Maastricht, Netherlands
[2] Radius Hlth Inc, Waltham, MA USA
[3] Univ Calif Los Angeles, Med Ctr, Cedars Sinai, Beverly Hills, CA USA
[4] Univ Liege, Liege, Belgium
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
10.1016/j.jval.2019.04.1136
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PMS26
引用
收藏
页码：S243 / S243
页数：1
相关论文
共 50 条
  • [41] EIGHTEEN MONTHS OF TREATMENT WITH ABALOPARATIDE FOLLOWED BY SIX MONTHS OF TREATMENT WITH ALENDRONATE IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS: RESULTS OF THE ACTIVEXTEND TRIAL
    Ferrari, S.
    Cosman, F.
    Miller, P.
    Hattersley, G.
    Williams, G.
    Hu, M.
    Riis, B. J.
    Christiansen, C.
    Fitzpatrick, L. A.
    OSTEOPOROSIS INTERNATIONAL, 2016, 27 : S40 - S40
  • [42] Cost-Effectiveness of Zoledronic Acid Versus Oral Alendronate for Postmenopausal Osteoporotic Women in China
    You, Ruxu
    Zhang, Yu
    Wu, David Bin-Chia
    Liu, Jinyu
    Qian, Xinyu
    Luo, Nan
    Moris, Takahiro
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [43] Cost-effectiveness of alendronate for the treatment of patients with low BMD and no prior fracture in Australia
    Defina, J
    Crowley, SJ
    Dalton, A
    Sen, SS
    OSTEOPOROSIS INTERNATIONAL, 2002, 13 : S45 - S45
  • [44] Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend Trial
    Cosman, Felicia
    Miller, Paul D.
    Williams, Gregory C.
    Hattersley, Gary
    Hu, Ming-yi
    Valter, Ivo
    Fitzpatrick, Lorraine A.
    Riis, Bente Juel
    Christiansen, Claus
    Bilezikian, John P.
    Black, Dennis
    MAYO CLINIC PROCEEDINGS, 2017, 92 (02) : 200 - 210
  • [45] Cost-effectiveness of buffered soluble alendronate 70 mg effervescent tablet for the treatment of postmenopausal women with osteoporosis in Italy
    M. Hiligsmann
    S. Maggi
    N. Veronese
    L. Sartori
    J.-Y. Reginster
    Osteoporosis International, 2021, 32 : 595 - 606
  • [46] Cost-effectiveness of buffered soluble alendronate 70 mg effervescent tablet for the treatment of postmenopausal women with osteoporosis in Italy
    Hiligsmann, M.
    Maggi, S.
    Veronese, N.
    Sartori, L.
    Reginster, J. -Y.
    OSTEOPOROSIS INTERNATIONAL, 2021, 32 (03) : 595 - 606
  • [47] Probability of Achieving BMD Treatment Targets with Abaloparatide and Teriparatide Over 18 Months and Sequential Abaloparatide vs Placebo Followed by Alendronate Over 3.5 Years
    Cosman, Felicia
    Mitlak, Bruce
    Wang, Yamei
    Caminis, John
    Moreira, Carolina
    Lewiecki, Michael
    Cummings, Steven
    JOURNAL OF BONE AND MINERAL RESEARCH, 2023, 38 : 324 - 325
  • [48] A COST-EFFECTIVENESS MODEL OF BAZEDOXIFENE VS. RALOXIFENE FOR THE PREVENTION OF FRACTURES IN SPANISH POSTMENOPAUSAL WOMEN
    Darba, Josep
    Perez-Alvarez, Nuria
    Kaskens, Lisette
    Racketa, Jill
    Rejas, Javier
    OSTEOPOROSIS INTERNATIONAL, 2011, 22 : 256 - 257
  • [49] Cost-effectiveness of once weekly alendronate plus vitamin D3 5600 IU combinaton therapy in the prevention of fractures in postmenopausal women with osteoporosts but without fracture history in the Netherlands
    Bergman, G. J. D.
    Fan, T.
    Sen, S. S.
    Jansen, J. P.
    CALCIFIED TISSUE INTERNATIONAL, 2008, 82 : S224 - S224
  • [50] A Cost-Effectiveness Model of Tibolone as Treatment for the Prevention of Osteoporotic Fractures in Postmenopausal Women in Sweden
    Michael Willis
    Knut Ödegaard
    Ulf Persson
    Johan Hedbrant
    Dan Mellström
    Mats Hammar
    Clinical Drug Investigation, 2001, 21 : 115 - 127
12345